Citius Oncology (CTOR) Change in Accured Expenses (2023 - 2026)

Citius Oncology (CTOR) has 4 years of Change in Accured Expenses data on file, last reported at $19.5 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 683.57% year-over-year to $19.5 million in Q1 2026; TTM through Mar 2026 was $15.3 million, a 77.31% increase from a year earlier, with the FY2025 full-year figure at $4.1 million, up 1679.92% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $19.5 million, up from $425792.0 in the prior quarter.
• Over the last five years, Change in Accured Expenses for CTOR reached as high as $19.5 million in Q1 2026 and fell as low as -$4.4 million in Q3 2025.
• Historically, Change in Accured Expenses has averaged $2.0 million across 4 years, with a median of $126025.0 in 2023.
• On a YoY basis, Change in Accured Expenses climbed as much as 3227.52% in 2024 and fell as far as 1724.88% in 2024.
• Year by year, Change in Accured Expenses stood at -$199155.0 in 2023, then surged by 3227.52% to $6.2 million in 2024, then tumbled by 93.16% to $425792.0 in 2025, then jumped by 4488.78% to $19.5 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were $19.5 million in Q1 2026, $425792.0 in Q4 2025, and -$4.4 million in Q3 2025.